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Obesity is a major health problem worldwide; it is associated with more than 30 medical conditions and is a
leading cause of unnecessary deaths. Adipose tissue not only acts as an energy store, but also behaves like an
endocrine organ, synthesising and secreting numerous hormones and cytokines. Angiotensin II (ANG II) is the
biologically active component of the renin-angiotensin system (RAS). The RAS is present in adipose tissue and
evidence suggests that ANG II is intimately linked to obesity. Indeed, ANG II increases fat cell growth and dif-
ferentiation, increases synthesis, uptake and storage of fatty acids and triglycerides and possibly inhibits lipolysis.
Evidence obtained using genetically modified animals has shown that the amount of body fat is directly related
to the amount of ANG II, i.e., animals with low levels of ANG II have reduced fat stores while animals with ex-
cessive ANG II have increased fat stores. In humans, epidemiological evidence has shown that body fat is corre-
lated with angiotensinogen, a precursor of ANG II, or other components of the RAS. Furthermore, blocking the
production and/or actions of ANG II with drugs or natural substances decreases body fat. The decrease in body
fat caused by such treatments predominantly occurs in abdominal fat depots and appears to be independent of
energy intake and digestibility. Clearly, ANG II has an important role in the accumulation of body fat and the
possibility exists that treatment of obesity will be enhanced by the use of natural or synthetic substances that in-
terfere with ANG II.
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Introduction mRNA in human adipocytes'^ and 3T3-L1 adipocytes,
Obesity, the excess accumulation of body fat due to an adipocytes derived from Swiss albino mice." Although
imbalance between energy intake and output, is reaching there is some contradictory evidence, possibly due to dif-
epidemic proportions and is a major health hazard world- ferences between the species and/or models examined,
wide. It is linked to the aetiology of a number of conditions there is still a considerable amount of data from both ani-
such as cardiovascular disease, hypertension, stroke and mal and human experiments suggesting that the RAS is
diabetes.'"'' Over-consumption of unhealthy food and mod- involved in the regulation of body fat and is therefore an
em technology has resulted in an alarming increase in the important factor in obesity,
incidence of obesity^ For example, in Australia, the preva-
lence of obesity has more than doubled over the past 20 The RAS
years.** In the USA, more than half of the population are In the classical RAS, AGT, a protein principally synthe-
obese or overweight' with the prevalence of obesity dou- sized in the liver, is converted to angiotensin I (ANG I) by
bling during the period from 1980 to 1999.* In China, there the action of renin, an enzyme mainly released from the
has been an increase, from 20.0% in 1992 to 29.9% in 2002, kidney. ANG I reaches the lungs via the circulation, where
in overweight individuals.'' '" France also followed this it is converted into angiotensin II (ANG II) by angiotensin-
trend; in 2003, 30% of the French adult population were converting enzyme (ACE). ANG II acts on the body
overweight and 11% obese" compared to the 1997 figures through angiotensin receptors type 1 and type 2 (ATIR and
of 23% and 7%, respectively.'^ AT2R) to increase blood pressure, thirst and fluid reten-
Various dietary, genetic and environmental factors are tion."' "" '^' All ofthe components ofthe RAS have been
believed to be responsible for the aetiology of obesity.
Within the last few decades, several studies have investi-
gated a possible link between obesity and the renin- Corresponding Author: Dr Richard S Weisinger, School of
angiotensin system (RAS), a system involved in body fluid Psychological Science, La Trobe University, Bundoora 3086,
and cardiovascular homeostasis.'^ For example, insulin, a Victoria, Australia.
key factor in the control of food intake and body weight''', Tel: +61-3-9479-2257; Fax: +61-3-9479-1956
has been shown to stimulate angiotensinogen (AGT) Email: r.weisinger@latrobe.edu.au
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identified in adipose tissue.^ '"^" Cathepsin and chymase,
also found in human adipocytes, can catalyse the conver-
sion of ANG I to ANG II.^ "*"^ ^ It is unclear whether the
production of ANG II in adipose tissue is due to the clas-
sical RAS system (ACE), the alternative enzymes or a
combination of the two. Overall, the data clearly demon-
strate the presence of a fully functional RAS in animal

















Figure 1. The renin angiotensin system; present in adipose
tissue.
Correlation of components ofthe RAS and body fat
Numerous reports have shown that components of the
RAS are correlated with body fat. During early develop-
ment and prior to there being a difference in body weight,
obese Zucker rats had increased body fat and secreted
significantly more AGT protein from adipose tissue than
their lean littermates.'" Evidence showing that secretion
of AGT was not solely related to adipocyte hypertrophy
suggested that locally produced AGT was involved in the
development of adipose tissue. In mice, a high-fat diet for
20 weeks resulted in increased AGT transcription in ab-
dominal fat (along with greater weight gain), suggesting
that the level of AGT changed with the weight ofthe mice
'^''. In rats that became obese on a moderately high fat
diet, compared to rats that were obesity resistant or that
were fed a low fat diet, AGT mRNA in retroperitoneal
adipose tissue and AGT in the circulation were in-
creased." Increased levels of RAS components and activ-
ity have been reported in obese humans '^" '^ and further-
more, these levels declined during weight loss."' '* Sub-
cutaneous and omental adipose tissue AGT mRNA was
positively correlated with waist-hip ratio in overweight
subjects^' and polymorphism of the ACE gene has been
linked to the incidence of obesity and alterations of body
mass index (BMI).^ * However, there is some contradic-
tory evidence. For example, it has been reported that AGT
mRNA was decreased in the adipose tissue of obese com-
pared to lean Zucker rats, yellow A '^' mice, and the rela-
tionship between adipose tissue and AGT mRNA was
variable in humans." Interestingly, it has been reported
that although relative to lean women, obese women had
decreased expression of AGT in adipose tissue, they had
increased AGT in the circulation.^' The existence of a
negative feedback loop was suggested such that AGT
expression in adipose tissue was decreased when plasma
levels become high. Although there are some exceptions,
there is evidence to suggest a positive correlation between
levels of AGT or other components of the RAS and the
level of body fat.
Role of the RAS in adipocyte differentiation and lipo-
genesis
Adipocytes are crucial to energy balance. Adipose tissue
mass is determined by adipocyte differentiation (the for-
mation of new adipocytes from precursor cells) and adi-
pocyte hypertrophy (increase in adipocyte cell size due to
fat storage). The RAS has been implicated as a trophic
factor in the differentiation of adipocytes. ANG II as well
as other components of the RAS are elevated in differen-
tiated cells.^' In quiescent preadipocytes harvested from
human adipose tissue, ANG II stimulated the progression
ofthe cell cycle. This was blocked by losartan, an ATI R
antagonist.^ ^
Evidence suggests that ANG II increases lipogenesis
and the triglyceride content of adipocytes"" (i.e., 3T3-L1
adipocytes). In regard to the mechanism by which ANG
II increased the triglyceride content of the cells, it was
observed that ANG II increased the activity of enzymes
involved in lipogenesis, fatty acid synthase (FAS), an
enzyme that catalyses the synthesis of palmitate from
acetyl CoA and malonyl CoA in the presence of
NADPH'", and glycerol-3-phosphate dehydrogenase
(GPDH), the rate-limiting enzyme for triglyceride synthe-
sis in adipose tissue. The increased activities of FAS and
GPDH were blocked by antagonists of either ATIR or
AT2R. Additionally, in experiments with human adipo-
cytes, as in 3T3-L1 cells, ANG II increased both FAS and
GPDH activities.
Some evidence suggests that the influence of ANG II
on differentiation of preadipocytes to adipocytes and li-
pogenesis are mediated through its stimulation of perox-
isome proliferators-activated receptor (PPAR) y'*^ , via
pathways that includes a number of different transcription
factors and/or prostacyclin (PGl2).''^ "''^  See Figure 2.
PGI2 is the major metabolite of arachidonic acid in adi-
pose tissue. It has been shown to cause adipose cell dif-
ferentiation in isolated adipocytes and adipose tissue
fragments derived from rats, mice and humans.'"'"^ Inter-
estingly, ANG II, via AT2R, increased PGI2 production in
adipocytes but not preadipocytes; once produced, how-
ever, the PGI2 stimulated differentiation of the preadipo-
cytes to adipocytes'''''"" PGI2 regulates expression of early
transcription factors ofthe family CCAAT/enhancer bind-
ing proteins, i.e., C/EBPp and C/EBP5.'"
ANG II has been shown to cause the up-regulation of
other transcription factors involved in adipocyte differen-
tiation, e.g., adipocyte differentiation determination-
dependent factor 1 (ADDl), sterol response element-
binding protein 1 (SREBPl).'"""
PPARs are members of the nuclear hormone receptor
superfamily, a group of nuclear proteins that mediate the
effects of small lipophilic compounds on DNA transcrip-
tion. '^' PPARy is necessary and sufficient to promote fat
cell differentiation and lipid accumulation." PPARa,












Figure 2. Possible pathways by which angiotensin II stimu-
lates cell differentiation and lipogenesis (ADDl, Adipocyte
Differentiation Determination-dependent factor 1; ANG II,
Angiotensin II; C/EBP, CCAAT Enhancer Binding Protein;
FAS, Fatty Acid Synthase; GPDH, Glycerol 3-phosphate De-
hydrogenase; PPAR, Peroxisome Proliferator Activated Recep-
tor; SREBP-lc, Sterol Regulatory Element Binding Protein
lc).
most abundant in liver, mediates the regulation of en-
zymes involved in fatty acid oxidation (e.g., camitine
palmitoyl transferase (CPT) -1, acyl CoA oxidase (ACO))
while PPARy, most abundant in adipose tissue, regulates
enzymes involved in differentiation (e.g., GPDH), lipo-
genesis (e.g., acetyl CoA carboxylase (ACC), FAS, glyc-
erol-3 phosphate acyl transferase (GPAT)) and in fatty
acid uptake and trapping (e.g., lipoprotein lipase (LPL)),
fatty acid transport protein CD 36)." PPARy agonists
(e.g., thiazolidinedione) stimulate adipogenesis and, in
general, increase body fat.""*" Treatment of obese Zucker
rats with irbesartan, an ATIR antagonist, reduced PPARy
and adipocyte differentiation^', a result consistent with the
adipogenic effect of ANG II and PPARy. However, as
will be described below, other evidence suggests that ir-
besartan, as well as some other ATIR antagonists, e.g.,
telmisartan, are PPARy partial agonists.
In spite of the evidence indicating that ANG II stimu-
lates adipogenesis and lipogenesis, a contrary view of the
role of ANG II has been proposed. Evidence based on
work using human adipocytes suggested that ANG II was
increased during adipogenesis and that ANG II, working
via ATI receptors, inhibited adipogenic differentiation
while blockade of ATIR causing enhanced adipogenesis.
It was proposed that the influence of ANG II was to in-
hibit the recruitment and differentiation of adipocytes'^'"
while RAS antagonists promoted the recruitment and dif-
ferentiation of adipocytes.''' Thus, ANG II would cause an
increase in fat cell size while antagonists would do the
opposite. Differences in the influence of the RAS on hu-
man and animal adipogenesis have been cited as the ex-
planation for the contradictory evidence. However, obser-
vations by CrandalP^ and Jones'^ using human adipose
cells seem to question this interpretation. Furthermore,
evidence obtained during in vivo microdialysis of human
adipose tissue"'" suggested that ANG II inhibited lipoly-
sis. Clearly, further work is required to clarify the mecha-
nisms responsible for the divergent results.
Relationship between the RAS, body fat accumulation
and body weight
Evidence from experiments involving genetically manipu-
lated animals or from experiments in which the activity of
the RAS was blocked suggests that the activity of the
RAS is directly related to accumulation of body fat. For
example, AGT-deficient mice (AGT-KO) gained less
weight than their wild-type (WT) counterparts despite
similar food intakes. The difference in body weights was
attributed to hypotrophy of adipocytes and a correspond-
ing decrease in adipose tissue mass. The AGT-KO and
WT mice appeared to have similar metabolic rates but the
AGT-KO mice displayed increased locomotor activity.
Decreased lipogenesis and increased motor activity was
thought to be responsible for the decrease in fat mass.'^
AT2R-deficient mice (AT2R '^") gained less weight than
their wild-type (WT) counterparts when maintained on a
high fat diet.*' The reduced body weight gain of the
AT2R-deficient mice was attributed to a lower food in-
take and increased energy expenditure; fat cell mass was
unchanged, hypotrophy of adipocytes was accompanied
by increased cell number. The AT2R-deficient mice had
increased whole-body lipid oxidation associated with a
decrease in FAS activity, PPARy and in genes associated
with the uptake and storage of fat (LPL, fatty acid trans-
port protein aP2 (a protein involved in fatty acid uptake
by adipocytes), CD36). Increased P-oxidation in muscle
was suggested by increased PPARa, fatty acid translocase,
CPT-1 and uncoupling protein (UCP)-3. These results are
consistent with the evidence showing that the ANG II-
induced increase in FAS is mediated via AT2R in mice.''"'
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In contrast, transgenic mice that over-expressed AGT
were shown to have a greater body weight than their con-
trol littermates. The difference in body weights was pri-
marily due to a 2-fold increase in body fat mass achieved
by adipocyte hypertrophy accompanied by hypoplasia of
the adipose cells. The increased fat mass was associated
with increased FAS activity and blood AGT levels. Food
intake and motor activity of the transgenic mice were
similar to those in the WT mice.™
The strongest evidence for a physiological role of the
RAS in control of body fat comes from studies in which
antagonists of the RAS have been administered. Although
there have been some exceptions""", administration of an
ACE inhibitor or a RAS antagonist has generally been
shown to reduce body weight and/or body weight gain.
Evidence has been obtained in experiments using sponta-
neously hypertensive rats, SHR' ' ' , Zucker obese rats'^
and humans." In addition to the decrease in body weight
observed in the obese Zucker rats, ACE inhibition in-
creased insulin-mediated glucose transport activity and
GLUT 4 protein in muscle." In rats fed a high fat diet''.
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administration of telmisartan but not valsartan, decreased
body weight and body fat (increased cell number and de-
creased cell size). The decreased body fat caused by
telmisartan was due to increased energy expenditure; nei-
ther food intake nor motor activity were altered. Also,
telmisartan increased expression of genes involved in
mitochondrial function and energy metabolism. The ex-
planation offered for the difference between telmisartan
and valsartan was that although both telmisartan and val-
sartan are ATIR antagonists, only the telmisartan has
partial PPARy agonist activity. In mice maintained on a
high fat diet, similar results were reported'^ i.e., telmisar-
tan decreased visceral adiposity and body weight without
altering food intake or locomotor activity. The telmisartan
treatment increased UCPl mRNA, a marker of energy
expenditure, in brown adipose tissue, and decreased
triglyceride uptake into white adipose tissue, liver and
skeletal muscle. Furthermore, telmisartan treatment de-
creased carbohydrate and increased fat metabolism.
In addition to the abovementioned changes, the telmis-
artan treatment increased adiponectin mRNA in white
adipose tissue. Increased adiponectin concentration has
been observed with some ACE inhibitors, e.g., enalapril,
and other ATIR blockers, e.g., irbesartan, losartan, can-
desartan.'^'" Adiponectin, an adipocytokine synthesized
in white adipocytes and induced during differentiation, is
an important signalling molecule between muscle and fat.
Adiponectin levels are inversely related to BMI and insu-
lin sensitivity."'*' Treatment with adiponectin stimulates
UCP-1 mRNA in brown adipose tissue, consistent with a
thermogenic action and increase in body temperature. '
Administration of adiponectin into the cerebrospinal fluid
of mice increased Fos in the paraventricular nucleus of
the hypothalamus, a key brain nucleus in energy homeo-
stasis.*^ Food intake is not altered by adiponectin and
decreased body weight is due to increased fatty acid oxi-
dation and energy utilisation*^"*'' via activation of AMP
kinase.*' Thus, although PPARy is integral to adipocyte
differentiation and lipogenesis, it also regulates adi-
ponectin secretion.*' Therefore, it is conceivable that the
decrease in body weight caused by telmisartan is a conse-
quence of the stimulation of adiponectin secretion by
PPARy.*'"*' Clearly, the contradictory roles proposed for
PPARy (e.g., stimulating mechanisms that result in an
increase or a decrease body fat), suggest that explanation
for the decrease in body weight caused by telmisartan is
not straight-forward and, presumably involves the differ-
ence in the conformational changes and consequences of
partial agonists in contrast to those of full agonists of
PPARy.'"'" Differential stimulation of PPARy subtypes
by different agonists/partial agonists may also be involved.
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Briefiy, the RAS seems to affect body composition and
weight regulation primarily via its infiuence on: (1) dif-
ferentiation of pre-adipocytes to mature adipocytes, (2)
promotion of transcription of the key lipogenic enzymes
(e.g., FAS and GPDH), resulting in increased fatty acid
synthesis and triglyceride storage, (3) inhibition of lipoly-
sis, and (4) inhibition of adiponectin, via ATIR.''' "
Some evidence suggests that interference with ANG II
production and/or action primarily reduces abdominal fat,
the fat implicated in insulin resistance and diabetes.'*''"'''
Interestingly, in addition to their well documented anti-
oxidant effects, the naturally occurring polyphenols in tea
have been shown to have ACE inhibitory activity." In
mice and rats maintained on high fat diets, green tea,
green tea extracts or isolated catechin constituents of tea,
in particular epicatechin gallate (EGCG), have been found
to reduce adipose tissue mass and body weight""" and to
increase endurance, metabolic rate and p-oxidation in
muscle and/or liver.'"" The decrease in body fat was as-
sociated with decreased expression of genes involved
fatty acid and lipid metabolism (stearoyl-CoA desaturase
(SCD)-l, GPAT, FAS, ACC-1) and the transcription fac-
tor, SREBP-1." In vitro, ECGC inhibited adipocyte dif-
ferentiation." In human studies, drinking tea has been
shown to increase energy expenditure and fat oxidation'"'
and reduce body fat'"^"'"", although not in all studies.'"^'
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Decreased body weight caused by infusion of ANG II:
A paradox
Despite the overwhelming evidence that ANG II stimu-
lates the synthesis and storage of fat and the observation
that reduction or elimination of the RAS by pharmacol-
ogical or genetic manipulation causes a decrease in body
fat, ANG II administration has been shown clearly to
cause weight loss in animals. Infusion of ANG II periph-
erally or into the brain of rats causes decreased body
weight compared to saline-infused or pair-fed animals.
" ' The decreased body weight has been observed to occur
with or without decreased food intake and, therefore, has
been attributed to increased energy expenditure (e.g., in-
creased thermogenesis). There is some evidence that the
increased energy expenditure is due to an ANG II-













Figure 3. Possible pathways by which angiotensin II causes
decreased body weight (ANG II, Angiotensin II; lGF-1, Insu-
lin-like Growth Factor 1)
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release of noradrenaiine'"'"'"', independent of ANG II-
induced hypertension.""''" The increased activation of
the sympathetic nervous system by ANG II is associated
with lipolysis and the loss of body fat. Lipolysis and de-
creased adipocyte size has been shown to occur in subcu-
taneous and visceral fat."^ The ANG Il-induced lipolysis
was blocked by losartan as well as by an adrenergic
blocker.
ANG Il-induced loss of body weight, however, has
been attributed primarily to muscle wasting due to en-
hanced protein degradation. In this regard, ANG II stimu-
lates glucocorticoid hormones that act to decrease insulin-
like growth factor (IGF)-l in blood and IGF-1 mRNA in
skeletal muscle."^' "" Subsequently, via an ubiquitin-
proteasome proteolytic pathway, there is an increase in
caspase-3 which leads to apoptosis ofthe muscle cells. "^
See Figure 3.
Another possible mechanism by which ANG II could
influence muscle wasting is through its influence on
leptin, a cytokine synthesised in fat. Leptin is upregulated
in obesity and promotes weight loss by decreasing food
intake and increasing energy expenditure. In addition,
leptin has effects in skeletal muscle, including an increase
in fatty acid oxidation and decrease in muscle protein
synthesis.*"''" Studies have shown that ANG II increases
both leptin secretion from human adipocytes'" and ex-
pression of the leptin (ob) gene in both human and 3T3-
Ll adipocytes."" Thus, it is possible that the effects of
ANG II on muscle degradation are mediated by leptin,
however, ANG II has been shown to decrease muscle
protein synthesis in v/7/-o."*''"
In a model of cancer cachexia, in which tumour growth
was associated with decreased food intake and body
weight and muscle wasting, antagonists of the RAS have
been shown to decrease the loss of body weight and the
loss of muscle mass and reduce tumour growth."'
One explanation for the paradoxical influence of in-
fused ANG II, either systemically or into the brain, is that
pathways not typically involved in the regulation of body
weight are stimulated. That is, under normal circum-
stances, the physiological level of ANG II achieved in
adipose tissue subsequent to its being stimulated, e.g., by
insulin, will cause cell-differentiation and lipogenesis. In
contrast, infused ANG II enhances the activity of systems
typically involved in body temperature regulation, e.g.,
sympathetic nervous system, and in the response to stress,
e.g., glucocorticoids. Thus, both body fat and body mus-
cle are decreased in spite of any ANG Il-induced adipo-
genesis. Interestingly, the body can adapt to the infused
ANG II and it has been shown that after one week of
ANG II treatment, body weight was decreased, however,
after two weeks of treatment, the body weight of ANG II-
treated rats was similar to that of control rats and lipo-
genesis in liver was increased in the ANG Il-treated ani-
mals.'^"
Conclusion
The presence of the major RAS components in adipose
tissue, effect of ANG II on fat cell growth, differentiation,
and synthesis, and the uptake and storage of fatty acids
and triglycerides point to the importance of the RAS in
body weight control. The evidence showing the ability of
compounds, both pharmacological and natural, that block
the production of ANG II to decrease body fat, and that
the loss of body fat caused by these treatments tend to
occur in abdominal fat depots, indicate that further re-
search into the natural and synthetic inhibitors ofthe RAS
is required. The conflicting data, produced primarily in
experiments in which ANG II is inflised into the whole
animal but also in experiments in which antagonists ofthe
RAS are used, again points to the need for further re-
search into systems and mechanisms infiuenced by the
RAS and antagonists of the RAS. Research into under-
standing of the adipose tissue RAS and how it is influ-
enced by the various treatments is crucial. At present,
however, it seems clear that antagonists of the RAS, both
natural and pharmacological, have the potential to be-
come vital to the treatment of the ever increasing problem
of obesity and insulin resistance.
Acknowledgements
This work was supported by the National Health and Medical
Research Council of Australia (Grant No. 21171 [RSW],
350313 [RSW, HSW, AJS]) and the Australian Research Coun-
cil (Grant No. DP0346830 [RSW, AJS, HSW]).
References
1. Haffner S, Taegtmeyer H. Epidemic obesity and the
metabolic syndrome. Circulation 2003; 108: 1541-1545.
2. Jung RT. Obesity as a disease. Br Med Bull 1997; 53:
307-321.
3. Proietto J, Baur LA. 10: Management of obesity. Med J
Aust 2004; 180:474-480.
4. Sharma AM. The obese patient with diabetes mellitus:
from research targets to treatment options. Am J Med
2006; 119: 17-23.
5. Hardus PM, van Vuuren CL, Crawford D, Worsley A.
Public perceptions ofthe causes and prevention of obesity
among primary school children. Int J Obes Relat Metab
Disord 2003; 27: 1465-1471.
6. Cameron AJ, Welbom TA, Zimmet PZ, Dunstan DW,
Owen N, Salmon J, Dalton M, JoUey D, Shaw JE. Over-
weight and obesity in Australia: the 1999-2000 Australian
Diabetes, Obesity and Lifestyle Study (AusDiab). Med J
Aust 2003; 178:427-432.
7. Finkelstein EA, Fiebelkom IC, Wang G. National medi-
eal spending attributable to overweight and obesity: how
much, and who's paying? Health Aff (Millwood) 2003;
Suppl Web Exclusives: W3-219-226.
8. Freedman DS, Khan LK, Serdula MK, Galuska DA,
Dietz WH. Trends and correlates of class 3 obesity in the
United States from 1990 through 2000. JAMA 2002; 288:
1758-1761.
9. Wang Y, Mi J, Shan XY, Wang QJ, GE KY. Is China
facing an obesity epidemic and the consequences? The
trends in obesity and chronic disease in China. Int J Obes
2007; 31: 177-188.
10. Wang H, Du S, Zhai F, Popkin BM. Trends in the distri-
bution of body mass index among Chinese adults, aged
20-45 years (1989-2000). Int J Obes (Lond) 2006 Jun 20;
[Epub ahead of print]
11. Bocquier A, BouUu-Ciocca S, Verger P, Oliver C. [Obe-
sity: where are we now?]. Presse Med 2006; 35: 270-276.
12. WHO. Diet, Nutrition and the Prevention of Chronic
Diseases. Technical Report. Geneva, Switzerland: World
Health Organisation; 2003 28 January - 1 February. Re-
port No. 916.
RS Weisinger, DP Begg, N Chen, M Jois, M Kwong, M Mathai and AJ Sindair 364
13. Guyton AC, Hall JE. Textbook of medical physiology.
10th ed. Philadelphia: W.B. Saunders; 2000.
14. Woods SC, Seeley RJ. Insulin as an adiposity signal. Int J
Obes 2001; 25: S35-38.
15. Harte AL, McTeman PG, McTeman CL, Smith SA, Bar-
nett AH, Kumar S. Insulin increases angiotensinogen ex-
pression in human abdominal subcutaneous adipocytes.
Diabetes Obes Metab 2003; 5: 302-310.
16. Jones BH, Standridge MK, Taylor JW, Moustaid N. An-
giotensinogen gene expression in adipose tissue: analysis
of obese models and hormonal and nutritional control.
Am J Physiol 1997; 273: R236-242.
17. Denton DA, McKinley MJ, Weisinger RS. Hypothalamic
integration of body fluid regulation. Proc Natl Acad Sei
USA 1996; 93: 7397-7404.
18. McKinley MJ, Allen AM, Mathai ML, May C, McAllen
RM, Oldfield BJ, Weisinger RS. Brain angiotensin and
body fluid homeostasis. Jpn J Physiol 2001; 51: 281-289.
19. McKinley MJ, McAllen RM, Pennington GL, Smarden-
eas A, Weisinger RS, Oldfield BJ. Physiological actions
of angiotensin II mediated by ATI and AT2 receptors in
the brain. Clin Exp Pharmacol Physiol Suppl 1996; 3:
S99-104.
20. Weisinger RS, Blair-West JR, Bums P, Denton DA,
McKinley MJ, Tarjan E. The role of angiotensin II in in-
gestive behaviour: a brief review of angiotensin II, thirst
and Na appetite. Regul Pept 1996; 66: 73-81.
21. Crandall DL, Herzlinger HE, Saunders BD, Armellino
DC, Krai JG. Distribution of angiotensin II receptors in
rat and human adipoeytes. J Lipid Res 1994; 35: 1378-
1385.
22. Crandall DL, Armellino DC, Busier DE, McHendry-
Rinde B, Krai JG. Angiotensin II receptors in human
preadipocytes: role in cell cycle regulation. Endocrinol-
ogy 1999; 140: 154-158.
23. Crandall DL, Herzlinger HE, Saunders BD, Zolotor RC,
Felieiano L, Cervoni P. Identification and characteriza-
tion of angiotensin II receptors in rat epididymal adipo-
cyte membranes. Metabolism 1993; 42: 511-515.
24. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson
B, Carlsson LM. Human adipose tissue expresses angio-
tensinogen and enzymes required for its conversion to
angiotensin IL J Clin Endocrinol Metab 1998; 83: 3925-
3929.
25. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A,
Sharma AM. Co-expression of renin-angiotensin system
genes in human adipose tissue. J Hypertens 1999; 17:
555-560.
26. Engeli S, Schling P, Gorzelniak K, Bosohmann M, Janke
J, Ailhaud G, Teboul M, Massiera F, Sharma AM. The
adipose-tissue renin-angiotensin-aldosterone system: role
in the metabolic syndrome? Int J Biochem Cell Biol 2003;
35: 807-825.
27. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-
Marc P, Teboul M. Angiotensinogen, angiotensin II and
adipose tissue development. Int J Obes Relat Metab Dis-
ord 2000; 24 Suppl 4: S33-35.
28. Goossens GH, Blaak EE, van Baak MA. Possible in-
volvement of the adipose tissue renin-angiotensin system
in the pathophysiology of obesity and obesity-related dis-
orders. Obes Rev 2003; 4: 43-55.
29. Schling P, Mallow H, Trindl A, Loffler G. Evidence for a
local renin angiotensin system in primary cultured human
preadipocytes. Int J Obes Relat Metab Disord 1999; 23:
336-341.
30. Hainault I, Nebout G, Turban S, Ardouin B, Ferre P,
Quignard-Boulange A. Adipose tissue-specific increase in
angiotensinogen expression and secretion in the obese
(fa/fa) Zucker rat. Am J Physiol 2002; 282: E59-66.
31. Rahmouni K, Mark AL, Haynes WG, Sigmund CD. Adi-
pose depot-specific modulation of angiotensinogen gene
expression in diet-induced obesity. Am J Physiol 2004;
286: E891-895.
32. Boustany CM, Bharadwaj K, Daugherty A, Brown DR,
Randall DC, Cassis LA. Activation of the systemic and
adipose renin-angiotensin system in rats with diet-
induced obesity and hypertension. Am J Physiol 2004;
287: R943-949.
33. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The
serum angiotensinogen concentration and variants of the
angiotensinogen gene in white and black children. J Clin
Invest 1995; 95: 948-953.
34. Cooper R, Forrester T, Ogunbiyi O, Muffinda J. Angio-
tensinogen levels and obesity in four black populations. J
Hypertens 1998; 16: 571-575.
35. Tuck ML, Sowers J, Domfeld L, Kledzik G, Maxwell M.
The effect of weight reduction on blood pressure, plasma
renin activity and plasma aldosterone levels in obese pa-
tients. N Engl J Med 1981; 304: 930-933.
36. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P,
Bader M, Luft FC, Sharma AM. Weight loss and the
renin-angiotensin-aldosterone system. Hypertension 2005;
45: 356-362.
37. Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-
Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I,
Bringman S, Amer P. The association of human adipose
angiotensinogen gene expression with abdominal fat dis-
tribution in obesity. Int J Obes Relat Metab Disord 2000;
24: 673-678.
38. StrazzuUo P, Iacone R, Iacoviello L, Russo O, Barba G,
Russo P, D'Orazio A, Barbato A, Cappuccio FP, Farinaro
E, Siani A. Genetic variation in the renin-angiotensin sys-
tem and abdominal adiposity in men: the Olivetti Pro-
spective Heart Study. Ann Intern Med 2003; 138: 17-23.
39. Saye JA, Lynch KR, Peach MJ. Changes in angiotensino-
gen messenger RNA in differentiating 3T3-F442A adipo-
eytes. Hypertension 1990; 15: 867-871.
40. Jones BH, Standridge MK, Moustaid N. Angiotensin II
increases lipogenesis in 3T3-L1 and human adipose cells.
Endocrinology 1997; 138: 1512-1519.
41. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and
its regulation. Annu Rev Bioehem 1983; 52: 537-579.
42. Gregoire FM, Smas CM, Sul HS. Understanding adipo-
cyte differentiation. Physiol Rev 1998; 78: 783-809.
43. Axelrod L, Minnich AK, Ryan CA. Stimulation of
prostacyclin production in isolated rat adipocytes by an-
giotensin II, vasopressin, and bradykinin: evidence for
two separate mechanisms of prostaglandin synthesis. En-
docrinology 1985; 116: 2548-2553.
44. Darimont C, Vassaux G, Ailhaud G, Negrel R. Differen-
tiation of preadipose cells: paracrine role of prostacyclin
upon stimulation of adipose cells by angiotensin-II. En-
docrinology 1994; 135: 2030-2036.
45. Darimont C, Vassaux G, Gaillard D, Ailhaud G, Negrel R.
In situ microdialysis of prostaglandins in adipose tissue:
stimulation of prostacyclin release by angiotensin II. Int J
Obes Relat Metab Disord 1994; 18: 783-788.
46. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel
R. Angiotensin II as a trophic factor of white adipose tis-
sue: stimulation of adipose cell formation. Endocrinology
2001; 142:487-492.
47. Negrel R, Gaillard D, Ailhaud G. Prostacyclin as a potent
effector of adipose-cell differentiation. Biochem J 1989;
257: 399-405.
365 Angiotensin and obesity
48. Vassaux G, Gaillard D, Ailhaud G, Negrel R. Prostacy-
clin is a specific effector of adipose cell differentiation. J
Biol Chem 1992; 267: 11092-11097.
49. Auhert J, Saint-Marc P, Belmonte N, Dani C, Negrel R,
Ailhaud G. Prostacyclin IP receptor up-regulates the early
expression of C/EBPbeta and C/EBPdelta in preadipose
cells. Mol Cell Endocrinol 2000; 160: 149-156.
50. Spiegelman BM. PPAR-gamma: adipogenic regulator and
thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
51. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adi-
pogenesis in fibrohlasts by PPAR gamma 2, a lipid-
activated transcription factor. Cell 1994; 79: 1147-1156.
52. Tontonoz P, Kim JB, Graves RA, Spiegelman BM.
ADD 1: a novel helix-loop-helix transcription factor asso-
ciated with adipocyte determination and differentiation.
Mol Cell Biol 1993; 13: 4753-4759.
53. Kim S, Dugail I, Standridge M, Claycombe K, Chun J,
Moustaid-Moussa N. Angiotensin Il-responsive element
is the insulin-responsive element in the adipocyte fatty
acid synthase gene: role of adipocyte determination and
differentiation factor 1/sterol-regulatory-element-binding
protein le. Biochem J 2001; 357: 899-904.
54. Kersten S. Peroxisome proliferator activated receptors
and obesity. European Joumal of Pharmacology 2002;
440: 223-234.
55. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM.
Transcriptional regulation of adipogenesis. Genes Dev
2000; 14: 1293-1307.
56. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma
and human metabolic disease. J Clin Invest 2006; 116:
581-589.
57. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison
WO, Willson TM, Kliewer SA. An antidiabetic thia-
zolidinedione is a high affinity ligand for peroxisome pro-
liferator-activated receptor gamma (PPAR gamma). J
Biol Chem 1995; 270: 12953-12956.
58. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman
BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2
is a ligand for the adipocyte determination factor PPAR
gamma. Cell 1995; 83: 803-812.
59. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W,
Laurent D, Burkey BF. Effects of pioglitazone on adipose
tissue remodeling within the setting of obesity and insulin
resistance. Diabetes 2001; 50: 1863-1871.
60. Larsen PJ, Jensen PB, Sorensen RV, Larsen LK, Vrang N,
Wulff EM, Wassermann K. Differential influences of
peroxisome proliferator-activated receptors gamma and -
alpha on food intake and energy homeostasis. Diabetes
2003; 52: 2249-2259.
61. Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda
F, Capuano A, D'Amico M. Effects of irbesartan on the
growth and differentiation of adipocytes in obese zucker
rats. Obes Res 2005; 13: 1909-1914.
62. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM.
Mature adipocytes inhibit in vitro differentiation of hu-
man preadipocytes via angiotensin type 1 receptors. Dia-
betes 2002; 51: 1699-1707.
63. Schling P, Loffler G. Effects of angiotensin II on adipose
conversion and expression of genes of the renin-
angiotensin system in human preadipocytes. Horm Metab
Res 2001; 33: 189-195.
64. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC.
Angiotensin blockade prevents type 2 diabetes by forma-
tion of fat cells. Hypertension 2002; 40: 609-611.
65. Jones BH, Standridge MK, Moustaid N. Angiotensin II
increases lipogenesis in 3T3-L1 and human adipose cells.
Endocrinology 1997; 138: 1512-1519.
66. Boschmann M, Ringel J, Klaus S, Sharma AM. Metabolic
and hemodynamic response of adipose tissue to angio-
tensin II. Obes Res 2001; 9: 486-491.
67. Goossens GH, Blaak EE, Saris WH, van Baak MA. An-
giotensin Il-induced effects on adipose and skeletal mus-
cle tissue blood flow and lipolysis in normal-weight and
obese subjects. J Clin Endoerinol Metab 2004; 89: 2690-
2696.
68. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A,
Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud
G, Teboul M. Angiotensinogen-deficient mice exhibit
impairment of diet-induced weight gain with alteration in
adipose tissue development and increased locomotor ac-
tivity. Endocrinology 2001; 142: 5220-5225.
69. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo
M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A.
Deletion of the angiotensin type 2 receptor (AT2R) re-
duces adipose cell size and protects from diet-induced
obesity and insulin resistance. Diabetes 2005; 54: 991-
999.
70. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fu-
kamizu A, Gasc JM, Quignard-Boulange A, Negrel R,
Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose
angiotensinogen is involved in adipose tissue growth and
blood pressure regulation. FASEB J 2001; 15: 2727-2729.
71. Bahi L, Koulmann N, Sanchez H, Momken I, Veksler V,
Bigard AX, Ventura-Clapier R. Does ACE inhibition en-
hance endurance performance and muscle energy metabo-
lism in rats? J Appl Physiol 2004; 96: 59-64.
72. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C,
Clemenz M, Krikov M, Thone-Reineke C, Unger T,
Kintscher U. PPARgamma-activating angiotensin type-1
receptor blockers induce adiponectin. Hypertension 2005;
46: 137-143.
73. Sugimoto K, Tsuruoka S, Fujimura A. Hyperlipidaemia
and the progression of nephropathy in OLETF rats: effect
of angiotensin-converting enzyme inhibitor, enalapril.
Clin Exp Pharmacol Physiol 1999; 26: 601-607.
74. Campbell DJ, Duncan AM, Kladis A, Harrap SB. Con-
verting enzyme inhibition and its withdrawal in sponta-
neously hypertensive rats. J Cardiovasc Pharmacol 1995;
26: 426-436.
75. Steen MS, Foianini KR, Youngblood EB, Kinnick TR,
Jacob S, Henriksen EJ. Interactions of exercise training
and ACE inhibition on insulin action in obese Zucker rats.
J Appl Physiol 1999; 86: 2044-2051.
76. Enalapril in essential hypertension: a comparative study
with propranolol. Enalapril in Hypertension Study Group
(UK). Br J Clin Pharmacol 1984; 18: 51-56.
77. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T,
Kurtz TW. Telmisartan but not valsartan increases caloric
expenditure and protects against weight gain and hepatic
steatosis. Hypertension 2006; 47: 1003-1009.
78. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T,
Yoshimatsu H. Telmisartan prevents obesity and in-
creases the expression of uncoupling protein 1 in diet-
induced obese miee. Hypertension 2006; 48: 51-57.
79. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka
M, Moniwa N, Yoshida D, Shimamoto K. Blockade of
the renin-angiotensin system increases adiponectin con-
centrations in patients with essential hypertension. Hyper-
tension 2003; 42: 76-81.
80. Argiles JM, Lopez-Soriano J, Almendro V, Busquets S,
Lopez-Soriano FJ. Cross-talk between skeletal muscle
and adipose tissue: a link with obesity? Med Res Rev
2005; 25: 49-65.













Haluzik M, Parizkova J, Haluzik MM. Adiponectin and 94.
its role in the obesity-induced insulin resistance and re-
lated complications. Physiol Res 2004; 53: 123-129.
Masaki T, Chiba S, Yasuda T, Tsubone T, Kakuma T, 95.
Shimomura I, Funahashi T, Matsuzawa Y, Yoshimatsu H.
Peripheral, but not central, administration of adiponectin
reduces visceral adiposity and upregulates the expression
of uncoupling protein in agouti yellow (Ay/a) obese mice. 96.
Diabetes 2003; 52: 2266-2273.
Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH,
Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in 97.
the brain to decrease body weight. Nat Med 2004; 10:
524-529.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Eriekson
MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage 98.
product of 30-kDa adipocyte complement-related protein
increases fatty acid oxidation in muscle and causes
weight loss in mice. Proc Natl Acad Sci USA 2001; 98:
2005-2010. 99.
Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H,
Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K,
Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D,
Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin 100.
stimulates glucose utilization and fatty-acid oxidation by
activating AMP-activated protein kinase. Nat Med 2002;
8: 1288-1295.
Neschen S, Morino K, Rossbacher JC, Pongratz RL, 101.
Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regu-
lates adiponectin secretion by a peroxisome proliferator-
activated receptor-gamma-dependent mechanism in mice.
Diabetes 2006; 55: 924-928. 102.
Bouskila M, Pajvani UB, Scherer PE. Adiponeetin: a
relevant player in PPARgamma-agonist-mediated im-
provements in hepatic insulin sensitivity? Int J Obes
(Lond) 2005; 29 Suppl 1: S17-23. 103.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke
R. Hormonal regulation of adiponectin gene expression in
3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;
290: 1084-1089. 104.
Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T,
Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural
A. Peroxisome proliferator-activated receptor gamma 105.
(PPAR-gamma) agonist increases plasma adiponectin
levels in type 2 diabetic patients with proteinuria. Endo-
crine 2004; 25: 207-214.
Pershadsingh HA. Treating the metabolic syndrome using 106.
angiotensin receptor antagonists that selectively modulate
peroxisome proliferator-activated receptor-gamma. Int J
Biochem Cell Biol 2006; 38: 766-781. 107.
Sehupp M, Clemenz M, Gineste R, Witt H, Janke J, Hel-
leboid S, Hennuyer N, Ruiz P, Unger T, Staels B,
Kintscher U. Molecular characterization of new selective 108.
peroxisome proliferator-activated receptor gamma modu-
lators with angiotensin receptor blocking activity. Diabe-
tes 2005; 54: 3442-3452. 109.
Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V,
Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK. Adipo-
cyte-specific gene expression and adipogenic steatosis in 110.
the mouse liver due to peroxisome proliferator-activated
receptor gammal (PPARgammal) overexpression. J Biol
Chem 2003; 278: 498-505.
Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada 111.
K, Adachi M. Angiotensin II infusion decreases plasma
adiponectin level via its type 1 receptor in rats: an impli-
cation for hypertension-related insulin resistance. Me-
tabolism 2006; 55: 478-488.
Kissebah AH, Peiris AN. Biology of regional body fat
distribution: relationship to non-insulin-dependent diabe-
tes mellitus. Diabetes Metab Rev 1989; 5: 83-109.
Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz
AJ, Kalkhoff RK, Adams PW. Relation of body fat distri-
bution to metabolic complications of obesity. J Clin En-
docrinol Metab 1982; 54: 254-260.
Actis-Goretta L, Ottaviani JI, Fraga CG. Inhibition of
angiotensin converting enzyme activity by flavanol-rich
foods. J Agric Food Chem 2006; 54: 229-234.
Wolfram S, Raederstorff D, Wang Y, Teixeira SR, Elste
V, Weber P. TEAVIGO (epigallocatechin gallate) sup-
plementation prevents obesity in rodents by reducing adi-
pose tissue mass. Ann Nutr Metab 2005; 49: 54-63.
Murase T, Haramizu S, Shimotoyodome A, Tokimitsu I,
Hase T. Green tea extract improves running endurance in
miee by stimulating lipid utilization during exercise. Am
J Physiol 2006; 290: R1550-1556.
Shimotoyodome A, Haramizu S, Inaba M, Murase T,
Tokimitsu I. Exercise and green tea extract stimulate fat
oxidation and prevent obesity in mice. Med Sci Sports
Exerc2005;37: 1884-1892.
Murase T, Haramizu S, Shimotoyodome A, Nagasawa A,
Tokimitsu I. Green tea extract improves endurance capac-
ity and increases muscle lipid oxidation in mice. Am J
Physiol 2005; 288: R708-715.
Rumpler W, Seale J, Clevidence B, Judd J, Wiley E, Ya-
mamoto S, Komatsu T, Sawaki T, Ishikura Y, Hosoda K.
Oolong tea increases metabolic rate and fat oxidation in
men. JNutr 2001; 131:2848-2852.
Hase T, Komine Y, Meguro S, Takeda Y, Takahashi H,
Matsui Y, Inaoke S, Katsuragi Y, Tokimitsu I, Shimasaki
H, Itakura H. Anti-obesity Effects of Tea Catechins in
Humans. J Oleo Sci 2001; 50: 599-605.
Nagao T, Komine Y, Soga S, Meguro S, Hase T, Tanaka
Y, Tokimitsu I. Ingestion of a tea rich in catechins leads
to a reduction in body fat and malondialdehyde-modified
LDL in men. Am J Clin Nutr 2005; 81: 122-129.
Tsuchida T, Itakura H, Nakamura H. Reduction of body
fat in humans by long-term ingestion of catechins. Prog
Med 2002; 22: 2189-2203.
Diepvens K, Kovacs EM, Nijs IM, Vogels N, Westerterp-
Plantenga MS. Effect of green tea on resting energy ex-
penditure and substrate oxidation during weight loss in
overweight females. Br J Nutr 2005; 94: 1026-1034.
Kovacs EM, Lejeune MP, Nijs I, Westerterp-Plantenga
MS. Effects of green tea on weight maintenance after
body-weight loss. Br J Nutr 2004; 91: 431-437.
English V, Cassis L. Facilitation of sympathetic neuro-
transmission contributes to angiotensin regulation of body
weight. J Neural Transm 1999; 106: 631-644.
Porter JP, Anderson JM, Robison RJ, Phillips AC. Effect
of central angiotensin II on body weight gain in young
rats. Brain Res 2003; 959: 20-28.
Porter JP, Potratz KR. Effect of intracerebroventricular
angiotensin II on body weight and food intake in adult
rats. Am J Physiol 2004; 287: R422-428.
Cassis LA, Marshall DE, Fettinger MJ, Rosenbluth B,
Lodder RA. Mechanisms contributing to angiotensin II
regulation of body weight. Am J Physiol 1998; 274:
E867-876.
Brink M, Wellen J, Delafontaine P. Angiotensin II causes
weight loss and decreases circulating insulin-like growth
factor I in rats through a pressor-independent mechanism.
J Clin Invest 1996; 97: 2509-2516.
367 Angiotensin and obesity
112. Cabassi A, Coghi P, Govoni P, Barouhiel E, Speroni E,
Cavazzini S, Cantoni AM, Scandroglio R, Fiaccadori E.
Sympathetic modulation by carvedilol and losartan re-
duces angiotensin Il-mediated lipolysis in subcutaneous
and visceral fat. J Clin Endocrinol Metab 2005; 90: 2888-
2897.
113. Brink M, Wellen J, Delafontaine P. Angiotensin II causes
weight loss and decreases circulating insulin-like growth
factor I in rats through a pressor-independent mechanism.
J Clin Invest 1996; 97: 2509-2516.
114. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch
WE, Delafontaine P. Angiotensin II induces skeletal
muscle wasting through enhanced protein degradation
and down-regulates autocrine insulin-like growth factor I.
Endocrinology 2001; 142: 1489-1496.
115. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafon-
taine P. Muscle-specific expression of IGF-1 blocks an-
giotensin Il-induced skeletal muscle wasting. J Clin In-
vest 2005; 115:451-458.
116. Hauner H. Secretory factors from human adipose tissue
and their functional role. Proc Nutr Soc 2005; 64: 163-
169.
117. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-
Moussa N. Angiotensin II increases leptin secretion by
3T3-L1 and human adipocytes via a prostaglandin-
independent mechanism. J Nutr 2002; 132: 1135-1140.
118. Russell ST, Sanders PM, Tisdale MJ. Angiotensin II di-
rectly inhibits protein synthesis in murine myotubes.
Cancer Lett 2006; 231: 290-294.
119. Sanders PM, Russell ST, Tisdale MJ. Angiotensin II di-
rectly induces muscle protein catabolism through the
ubiquitin-proteasome proteolytic pathway and may play a
role in cancer cachexia. Br J Cancer 2005; 93: 425-434.
120. Ran J, Hirano T, Adachi M. Chronic ANG II infusion
increases plasma triglyceride level by stimulating hepatic
triglyceride production in rats. Am J Physiol 2004; 287:
E955-961.

